Sjögren's syndrome: a systemic autoimmune disease

S Negrini, G Emmi, M Greco, M Borro… - Clinical and …, 2022 - Springer
Sjögren's syndrome is a chronic autoimmune disease characterized by ocular and oral
dryness resulting from lacrimal and salivary gland dysfunction. Besides, a variety of systemic …

Pathogenesis and treatment of Sjogren's syndrome: review and update

Q Zhan, J Zhang, Y Lin, W Chen, X Fan… - Frontiers in …, 2023 - frontiersin.org
Sjogren's syndrome (SS) is a chronic autoimmune disease accompanied by multiple
lesions. The main manifestations include dryness of the mouth and eyes, along with …

[HTML][HTML] The diagnosis and treatment of Sjögren's syndrome

AL Stefanski, C Tomiak, U Pleyer… - Deutsches Ärzteblatt …, 2017 - ncbi.nlm.nih.gov
Background Sjögren's syndrome is one of the more common inflammatory rheumatological
diseases, with a prevalence of at least 0.4% in Germany. Methods This review is based on …

[HTML][HTML] A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome

X Mariette, F Barone, C Baldini, H Bootsma, KL Clark… - JCI insight, 2022 - ncbi.nlm.nih.gov
BACKGROUND Primary Sjögren's syndrome (pSS) is characterized by B cell hyperactivity
and elevated B-lymphocyte stimulator (BLyS). Anti-BLyS treatment (eg, belimumab) …

Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

R Felten, V Devauchelle-Pensec, R Seror… - Annals of the …, 2021 - ard.bmj.com
Objectives No immunomodulatory drug has been approved for primary Sjögren's syndrome,
a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the …

Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial

AN Baer, JE Gottenberg, EW St Clair… - Annals of the …, 2021 - ard.bmj.com
Objectives To evaluate efficacy and safety of abatacept in adults with active primary
Sjögren's syndrome (pSS) in a phase III, randomised, double-blind, placebo-controlled trial …

Microbiota dysbiosis in primary Sjögren's syndrome and the ameliorative effect of hydroxychloroquine

X Wang, K Pang, J Wang, B Zhang, Z Liu, S Lu, X Xu… - Cell Reports, 2022 - cell.com
The human microbiome plays an important role in autoimmune diseases. However, there is
limited knowledge regarding the microbiota in individuals with primary Sjögren's syndrome …

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of …

BA Fisher, A Szanto, WF Ng, M Bombardieri… - The Lancet …, 2020 - thelancet.com
Summary Background Primary Sjögren's syndrome is an autoimmune disease that presents
as dryness of the mouth and eyes due to impairment of the exocrine glands. To our …

Sjögren's syndrome: more than just dry eye

EK Akpek, VY Bunya, IJ Saldanha - Cornea, 2019 - journals.lww.com
Purpose: Sjögren's syndrome (SS) is a common autoimmune disease affecting about four
million Americans. Although approximately 1 in 10 patients with clinically-significant …

Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations

P Brito-Zerón, E Theander, C Baldini… - Expert review of …, 2016 - Taylor & Francis
Sjögren's syndrome (SjS) is a systemic autoimmune disease that mainly affects the exocrine
glands, leading to generalized mucosal dryness. However, primary SjS may initially present …